As of September 30, 2025, the Company had cash, cash equivalents and marketable securities of $391.7 million, which includes proceeds from its upsized public offering. Based on its current operating plan, management expects the combined cash and marketable securities balance to fund operations into 2029.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- DraftKings, Flutter downgraded: Wall Street’s top analyst calls
- 3 Best Stocks to Buy Now, 11/4/2025, According to Top Analysts
- Buy Rating for MBX Biosciences Driven by Promising PEP Platform and Successful Phase II Trials
- MBX Biosciences initiated with a Buy at TD Cowen
- MBX Biosciences Advances Phase 2a Study on PBH Treatment with Imapextide